Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2-10 ng/ml

被引:84
作者
Ferro, Matteo [3 ,6 ]
Bruzzese, Dario [2 ]
Perdona, Sisto [1 ]
Marino, Ada [4 ]
Mazzarella, Claudia [4 ]
Perruolo, Giuseppe [4 ]
D'Esposito, Vittoria [4 ]
Cosimato, Vincenzo [4 ]
Buonerba, Carlo [5 ]
Di Lorenzo, Giuseppe [5 ]
Musi, Gennaro [6 ]
De Cobelli, Ottavio [6 ]
Chun, Felix K. [7 ]
Terracciano, Daniela [4 ]
机构
[1] Fdn G Pascale, Urol Unit, Naples, Italy
[2] Univ Naples Federico II, Dept Prevent Med Sci, Naples, Italy
[3] Univ Naples Federico II, Urol Unit, Naples, Italy
[4] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy
[5] Univ Naples Federico II, Oncol Unit, Naples, Italy
[6] European Inst Oncol, Div Urol, Milan, Italy
[7] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany
关键词
ISOFORM P2PSA; MULTICENTER; PREDICTION; SERUM; DERIVATIVES; VALIDATION; OUTCOMES;
D O I
10.1371/journal.pone.0067687
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Many efforts to reduce prostate specific antigen (PSA) overdiagnosis and overtreatment have been made. To this aim, Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) have been proposed as new more specific biomarkers. We evaluated the ability of phi and PCA3 to identify prostate cancer (PCa) at initial prostate biopsy in men with total PSA range of 2-10 ng/ml. The performance of phi and PCA3 were evaluated in 300 patients undergoing first prostate biopsy. ROC curve analyses tested the accuracy (AUC) of phi and PCA3 in predicting PCa. Decision curve analyses (DCA) were used to compare the clinical benefit of the two biomarkers. We found that the AUC value of phi (0.77) was comparable to those of %p2PSA (0.76) and PCA3 (0.73) with no significant differences in pairwise comparison (%p2PSA vs phi p = 0.673, %p2PSA vs. PCA3 p = 0.417 and phi vs. PCA3 p = 0.247). These three biomarkers significantly outperformed fPSA (AUC = 0.60), %fPSA (AUC = 0.62) and p2PSA (AUC = 0.63). At DCA, phi and PCA3 exhibited a very close net benefit profile until the threshold probability of 25%, then phi index showed higher net benefit than PCA3. Multivariable analysis showed that the addition of phi and PCA3 to the base multivariable model (age, PSA, %fPSA, DRE, prostate volume) increased predictive accuracy, whereas no model improved single biomarker performance. Finally we showed that subjects with active surveillance (AS) compatible cancer had significantly lower phi and PCA3 values (p < 0.001 and p = 0.01, respectively). In conclusion, both phi and PCA3 comparably increase the accuracy in predicting the presence of PCa in total PSA range 2-10 ng/ml at initial biopsy, outperforming currently used %fPSA.
引用
收藏
页数:7
相关论文
共 25 条
[1]   Contemporary Role of Prostate Cancer Antigen 3 in the Management of Prostate Cancer [J].
Auprich, Marco ;
Bjartell, Anders ;
Chun, Felix K. -H. ;
de la Taille, Alexandre ;
Freedland, Stephen J. ;
Haese, Alexander ;
Schalken, Jack ;
Stenzl, Arnulf ;
Tombal, Bertrand ;
van der Poel, Henk .
EUROPEAN UROLOGY, 2011, 60 (05) :1045-1054
[2]   External Validation of Urinary PCA3-Based Nomograms to Individually Predict Prostate Biopsy Outcome [J].
Auprich, Marco ;
Haese, Alexander ;
Walz, Jochen ;
Pummer, Karl ;
de la Taille, Alexandre ;
Graefen, Markus ;
de Reijke, Theo ;
Fisch, Margit ;
Kil, Paul ;
Gontero, Paolo ;
Irani, Jacques ;
Chun, Felix K. -H. .
EUROPEAN UROLOGY, 2010, 58 (05) :727-732
[3]   A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range [J].
Catalona, William J. ;
Partin, Alan W. ;
Sanda, Martin G. ;
Wei, John T. ;
Klee, George G. ;
Bangma, Chris H. ;
Slawin, Kevin M. ;
Marks, Leonard S. ;
Loeb, Stacy ;
Broyles, Dennis L. ;
Shin, Sanghyuk S. ;
Cruz, Amabelle B. ;
Chan, Daniel W. ;
Sokoll, Lori J. ;
Roberts, William L. ;
van Schaik, Ron H. N. ;
Mizrahi, Isaac A. .
JOURNAL OF UROLOGY, 2011, 185 (05) :1650-1655
[4]   The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy [J].
Durand, Xavier ;
Xylinas, Evanguelos ;
Radulescu, Camelia ;
Haus-Cheymol, Rachel ;
Moutereau, Stephane ;
Ploussard, Gillaume ;
Forgues, Aurelien ;
Robert, Gregoire ;
Vacherot, Francis ;
Loric, Sylvain ;
Allory, Yves ;
Ruffion, Alain ;
de la Taille, Alexandre .
BJU INTERNATIONAL, 2012, 110 (01) :43-49
[5]   The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma [J].
Epstein, JI ;
Allsbrook, WC ;
Amin, MB ;
Egevad, LL ;
Bastacky, S ;
Beltrán, AL ;
Berner, A ;
Billis, A ;
Boccon-Gibod, L ;
Cheng, L ;
Civantos, F ;
Cohen, C ;
Cohen, MB ;
Datta, M ;
Davis, C ;
Delahunt, B ;
Delprado, W ;
Eble, JN ;
Foster, CS ;
Furusato, M ;
Gaudin, PB ;
Grignon, DJ ;
Humphrey, PA ;
Iczkowski, KA ;
Jones, EC ;
Lucia, S ;
McCue, PA ;
Nazeer, T ;
Oliva, E ;
Pan, CC ;
Pizov, G ;
Reuter, V ;
Samaratunga, H ;
Sebo, T ;
Sesterhenn, I ;
Shevchuk, M ;
Srigley, JR ;
Suzigan, S ;
Takahashi, H ;
Tamboli, P ;
Tan, PH ;
Têtu, B ;
Tickoo, S ;
Tomaszewski, JE ;
Troncoso, P ;
Tsuzuki, T ;
True, LD ;
van der Kwast, T ;
Wheeler, TM ;
Wojno, KJ .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (09) :1228-1242
[6]   Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers [J].
Ferro, Matteo ;
Bruzzese, Dario ;
Perdona, Sisto ;
Mazzarella, Claudia ;
Marino, Ada ;
Sorrentino, Alessandra ;
Di Carlo, Angelina ;
Autorino, Riccardo ;
Di Lorenzo, Giuseppe ;
Buonerba, Carlo ;
Altieri, Vincenzo ;
Mariano, Angela ;
Macchia, Vincenzo ;
Terracciano, Daniela .
CLINICA CHIMICA ACTA, 2012, 413 (15-16) :1274-1278
[7]   APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer [J].
Groskopf, Jack ;
Aubin, Sheila M. J. ;
Deras, Ina Lim ;
Blase, Amy ;
Bodrug, Sharon ;
Clark, Craig ;
Brentano, Steven ;
Mathis, Jeannette ;
Pham, Jimmykim ;
Meyer, Troels ;
Cass, Michelle ;
Hodge, Petrea ;
Macairan, Maria Luz ;
Marks, Leonard S. ;
Rittenhouse, Harry .
CLINICAL CHEMISTRY, 2006, 52 (06) :1089-1095
[8]   Preoperative Prostate-Specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer [J].
Guazzoni, Giorgio ;
Lazzeri, Massimo ;
Nava, Luciano ;
Lughezzani, Giovanni ;
Larcher, Alessandro ;
Scattoni, Vincenzo ;
Gadda, Giulio Maria ;
Bini, Vittorio ;
Cestari, Andrea ;
Buffi, Nicolo Maria ;
Freschi, Massimo ;
Rigatti, Patrizio ;
Montorsi, Francesco .
EUROPEAN UROLOGY, 2012, 61 (03) :455-466
[9]   Prostate-Specific Antigen (PSA) Isoform p2PSA Significantly Improves the Prediction of Prostate Cancer at Initial Extended Prostate Biopsies in Patients with Total PSA Between 2.0 and 10 ng/ml: Results of a Prospective Study in a Clinical Setting [J].
Guazzoni, Giorgio ;
Nava, Luciano ;
Lazzeri, Massimo ;
Scattoni, Vincenzo ;
Lughezzani, Giovanni ;
Maccagnano, Carmen ;
Dorigatti, Fernanda ;
Ceriotti, Ferruccio ;
Pontillo, Marina ;
Bini, Vittorio ;
Freschi, Massimo ;
Montorsi, Francesco ;
Rigatti, Patrizio .
EUROPEAN UROLOGY, 2011, 60 (02) :214-222
[10]   A note on adaptive Bonferroni and Holm procedures under dependence [J].
Guo, Wenge .
BIOMETRIKA, 2009, 96 (04) :1012-1018